Indivumed and Wilmot Cancer Institute Partner to Accelerate Precision Oncology Research
Table of Contents
A new collaboration between Indivumed and the Wilmot Cancer Institute at the University of Rochester Medical Center (URMC) promises to accelerate the development of personalized cancer therapies, leveraging advanced data analysis and rapid tissue processing techniques. The partnership, announced December 10, 2025, builds on a history of successful joint research and aims to create a extensive resource for patient-centered cancer research and drug development.
Minimizing Ischemia Time for Optimal Sample Integrity
A key component of the partnership is a focus on minimizing ischemia time – the period tissue samples are without blood supply. The collaboration aims to reduce this time to less than ten minutes, ensuring the integrity and quality of the samples for research purposes. This rapid processing is crucial for accurate analysis and the development of reliable patient-derived tumor models.
Developing Patient-Derived Tumor models for Drug Finding
The joint research efforts will prioritize the creation of well-characterized patient-derived tumor models from collected samples. these models, including cell cultures, spheroids, and organoids, will be combined with comprehensive data to identify, validate, and screen potential molecular targets for cancer pharmaceuticals. This approach aims to “de-risk” the drug development process and accelerate the identification of effective therapies.
Expert Optimism and Collaborative History
“We have worked successfully with Indivumed in the past and our familiarity with their approach to tissue and multi-omics data will provide an excellent foundation,” stated a senior official at the Wilmot cancer Institute. “The new project will provide greater opportunities to identify new therapies and biomarkers, uncover insights into the correct target-patient match for clinical decision-making, and thereby help advance cancer care.”
Focus on Advanced Solid Cancers
Initially, the collaboration will focus on advanced stages of solid cancers with notable medical need, including colorectal cancer, pancreatic cancer, lung cancer, and breast cancer. There is potential for expansion into other cancer types in the future. The knowledge gained will contribute to Indivumed’s ongoing research and provide clinicians with guidance for therapeutic decision-making.
AI-Powered Data Analysis and Global Network Expansion
Indivumed’s CEO and founder emphasized the role of their unique AI-powered data analysis capabilities in identifying new cancer therapies. “We will develop primary tumor models to test new compounds against targets that have been identified… in order to bring new therapeutics to patients as quickly and precisely as possible,” he said. The partnership also expands URMC’s reach within Indivumed’s global clinical network, which includes leading oncology institutes in North America, Europe, and Asia. This collaboration builds on previous joint research, including a recent publication detailing a novel method for classifying colon cancer subtypes.
About the Institutions
The Wilmot Cancer Institute at the University of Rochester serves a population of over three million people across 27 counties in new York State. The institute comprises over 190 oncology physicians, 500 nurses, and 115 scientists dedicated to cancer research and care. Indivumed is committed to redefining oncology through the identification and development of best-in-class therapeutic products, leveraging over twenty years of experience in standardized tissue collection and analysis.
For media inquiries, contact Kristin Maack at Indivumed ([email protected]) or Kellie Fraver at the University of Rochester Medical Center/Wilmot Cancer Institute ([email protected] or +1-585-314-1552).
